Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Change in Accured Expenses (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Change in Accured Expenses for 6 consecutive years, with -$37693.0 as the latest value for Q4 2021.

  • Quarterly Change in Accured Expenses rose 90.36% to -$37693.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $491104.0 through Dec 2021, up 158.82% year-over-year, with the annual reading at $113287.0 for FY2025, 156.97% up from the prior year.
  • Change in Accured Expenses for Q4 2021 was -$37693.0 at ENDRA Life Sciences, up from -$65736.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $818065.0 in Q2 2021, with the low at -$390823.0 in Q4 2020.
  • Average Change in Accured Expenses over 5 years is $53546.0, with a median of -$51714.5 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 665.83% in 2019, while the deepest fall reached 1263.08% in 2019.
  • Over 5 years, Change in Accured Expenses stood at $536173.0 in 2017, then plummeted by 117.49% to -$93756.0 in 2018, then surged by 665.83% to $530503.0 in 2019, then crashed by 173.67% to -$390823.0 in 2020, then skyrocketed by 90.36% to -$37693.0 in 2021.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$37693.0, -$65736.0, and $818065.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.